Milestone Pharmaceuticals... (MIST)

NASDAQ: MIST · Real-Time Price · USD

1.32

0.00 (0.00%)

At close: May 01, 2025, 3:59 PM

1.33

0.38%

After-hours: May 01, 2025, 06:00 PM EDT

0.00% (1D)

Bid	1.28
Market Cap	70.69M
Revenue (ttm)	n/a
Net Income (ttm)	-41.52M
EPS (ttm)	-0.67
PE Ratio (ttm)	-1.98
Forward PE	-1.01
Analyst	Buy

Ask	1.4
Volume	720,236
Avg. Volume (20D)	2,566,134
Open	1.31
Previous Close	1.32
Day's Range	1.28 - 1.36
52-Week Range	0.63 - 2.75
Beta	1.38

About MIST

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date May 9, 2019

Employees 33

Stock Exchange NASDAQ

Ticker Symbol MIST

Website https://www.milestonepharma.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for MIST stock is "Buy." The 12-month stock price forecast is $9.5, which is an increase of 616.98% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

-60.89%

Milestone Pharmaceuticals shares are trading lower... Unlock content with Pro Subscription

8 months ago

+2.86%

Milestone Pharmaceuticals shares are trading higher after Rodman & Renshaw initiated coverage on the stock with a Buy rating and announced a $9 price target.

News

4 weeks ago · seekingalpha.com

Stock Picks From Seeking Alpha's March 2025 New Analysts

In March, we welcomed 30 new analysts to Seeking Alpha, and in this article we are showcasing their stock picks and investment strategies. Our analysts covered a diverse set of industries—including IT...

1 month ago · zacks.com

MIST Stock Falls 66% Following Complete Response Letter for Cardamyst

Milestone Pharmaceuticals faces an FDA setback for its PSVT nasal spray. The company coordinates with regulatory authorities to resolve CRL issues.

1 month ago · reuters.com

US FDA declines to approve Milestone Pharma's heart rhythm nasal spray

The U.S. Food and Drug Administration has declined to approve Milestone Pharmaceuticals' nasal spray to treat a type of heart condition, the company said on Friday.

1 month ago · seekingalpha.com

Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers

In December 2023, Milestone Pharmaceuticals received an RTF letter from the FDA for insufficient TEAE data in their NDA filing, which precipitated a rapid decline in its share price. With an upcoming ...